328546-73-2Relevant academic research and scientific papers
Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
-
Page/Page column 47-48, (2008/06/13)
The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.
Clozapine derived 2,3-dihydro-1H-1,4- and 1,5-benzodiazepines with D4 receptor selectivity: Synthesis and biological testing
Hussenether, Thomas,Huebner, Harald,Gmeiner, Peter,Troschuetz, Reinhard
, p. 2625 - 2637 (2007/10/03)
Novel 4-arylpiperazin-1-yl-substituted 2,3-dihydro-1H-1,4- and 1H-1,5-benzodiazepines and their aza-analogues were synthesized as debenzoclozapine derivatives for evaluation as potential D4-ligands. While Ki values of some of the title compounds came within the range of clozapine, they showed an impressively greater selectivity over other dopamine receptor subtypes, especially D2. For the most promising compounds, intrinsic activity and binding properties to serotonin 5-HT1A and 5-HT2 were also determined.
4,5-DIHYDRO-IMIDAZO[4,5,1-II]QUINOLIN-6-ONES AS PARP INHIBITORS
-
Page 15, (2008/06/13)
Compounds of the formula 1, in which R1 and R2 have the meanings indicated in the description, are novel active PARP inhibitors.
